Scientific Publications by FDA Staff
J Transl Med 2011 Apr 8;9:37
Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer.
Fujisawa T, Joshi BH, Puri RK
BACKGROUND: Interleukin-13 Receptor ¿2 (IL-13R¿2) is a tumor-associated antigen and target for cancer therapy. Since IL-13R¿2 is heterogeneously overexpressed in a variety of human cancers, it would be highly desirable to uniformly upregulate IL-13R¿2 expression in tumors for optimal targeting. METHODS: We examined epigenetic regulation of IL-13R¿2 in a murine model of human pancreatic cancer by Bisulfite-PCR, sequencing for DNA methylation and chromatin immunoprecipitation for histone modification. Reverse transcription-PCR was performed for examining changes in IL-13R¿2 mRNA expression after treatment with histone deacetylase (HDAC) and c-jun inhibitors. In vitro cytotoxicity assays and in vivo testing in animal tumor models were performed to determine whether HDAC inhibitors could enhance anti-tumor effects of IL-13-PE in pancreatic cancer. Mice harboring subcutaneous tumors were treated with HDAC inhibitors systemically and IL-13-PE intratumorally. RESULTS: We found that CpG sites in IL-13R¿2 promoter region were not methylated in all pancreatic cancer cell lines studied including IL-13R¿2-positive and IL-13R¿2-negative cell lines and normal cells. On the other hand, histones at IL-13R¿2 promoter region were highly-acetylated in IL-13R¿2-positive but much less in receptor-negative pancreatic cancer cell lines. When cells were treated with HDAC inhibitors, not only histone acetylation but also IL-13R¿2 expression was dramatically enhanced in receptor-negative pancreatic cancer cells. In contrast, HDAC inhibition did not increase IL-13R¿2 in normal cell lines. In addition, c-jun in IL-13R¿2-positive cells was expressed at higher level than in negative cells. Two types of c-jun inhibitors prevented increase of IL-13R¿2 by HDAC inhibitors. HDAC inhibitors dramatically sensitized cancer cells to immunotoxin in the cytotoxicity assay in vitro and increased IL-13R¿2 in the tumors subcutaneously implanted in the immunodeficient animals but not in normal mice tissues. Combination therapy with HDAC inhibitors and immunotoxin synergistically inhibited growth of not only IL-13R¿2-positive but also IL-13R¿2-negative tumors. CONCLUSIONS: We have identified a novel function of histone modification in the regulation of IL-13R¿2 in pancreatic cancer cell lines in vitro and in vivo. HDAC inhibition provides a novel opportunity in designing combinatorial therapeutic approaches not only in combination with IL-13-PE but with other immunotoxins for therapy of pancreatic cancer and other cancers.
|Category: Journal Article|
|PubMed ID: #21477288||DOI: 10.1186/1479-5876-9-37|
|PubMed Central ID: #PMC3096924|
|Includes FDA Authors from Scientific Area(s): Biologics|
|Entry Created: 2011-10-03||Entry Last Modified: 2012-08-29|